Unbiased AI-powered news
1 stories related to this topic, newest first.
Substrate placeholder — needs reviewInsmed Incorporated announced the discontinuation of its topical drug TPX-201 for hidradenitis suppurativa following negative results from a Phase 2 clinical trial. The trial did not meet its primary endpoint of achieving Hidradenitis Suppurativa Clinical Response at Week 12. The…